Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation

Abstract Objectives B cell depletion by rituximab (RTX) is an effective treatment for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV). However, peripheral B cell phenotypes and the selection criteria for RTX therapy in AAV remain unclear. Methods Phenotypic characterizati...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yusuke Miyazaki, Shingo Nakayamada, Satoshi Kubo, Yuichi Ishikawa, Maiko Yoshikawa, Kei Sakata, Shigeru Iwata, Ippei Miyagawa, Kazuhisa Nakano, Yoshiya Tanaka
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2020-06-01
coleção:	Arthritis Research & Therapy
Assuntos:	ANCA-associated vasculitis B cell Rituximab
Acesso em linha:	http://link.springer.com/article/10.1186/s13075-020-02215-x
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!